Article
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Cancer research - 15 Mar 2006
Alvarez James V, Greulich Heidi, Sellers William R, Meyerson Matthew, Frank David A
Abstract excerpt
Somatic mutations in the epidermal growth factor receptor (EGFR) occur frequently in lung cancer and confer sensitivity to EGFR kinase inhibitors gefitinib and erlotinib. These mutations, which occur in the kinase domain of the protein, also render EGFR constitutively active and transforming. Signal transducers and activators of transcription 3 (STAT3) transduces signals from a number of oncogenic tyrosine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.